Table 1. CH defined by both acquired mCA and/or driver somatic mutations.

Participants	Discovery cohort					Validation cohort					Total
	Males		Female		Total	Males		Females		Total
	N	%	N	%		N	%	N	%
Total number	45198	45%	55118	55%	100316	44956	45%	55359	55%	100315	200631
All CH	1286	45%	1582	55%	2868	1335	47%	1515	53%	2850	5718
Myeloid CH a	831	46%	960	54%	1791	885	49%	912	51%	1797	3588
Lymphoid CH b	135	48%	146	52%	281	140	46%	167	54%	307	588
All mCA	431	42%	585	58%	1016	439	44%	561	56%	1000	2016
Myeloid mCA	48	53%	42	47%	90	54	57%	41	43%	95	185
Lymphoid mCA	57	50%	56	50%	113	60	48%	64	52%	124	237
Other mCA	326	40%	487	60%	813	325	42%	456	58%	781	1594
All driver mutations	894	47%	1027	53%	1921	941	48%	1001	52%	1942	3863
Myeloid genes c,d	805	46%	933	54%	1738	854	49%	890	51%	1744	3482
DNMT3A	295	39%	470	61%	765	348	45%	419	55%	767	1532
TET2	193	46%	225	54%	418	188	46%	217	54%	405	823
ASXL1	103	64%	59	36%	162	92	64%	51	36%	143	305
JAK2	37	58%	27	42%	64	46	57%	35	43%	81	145
Other myeloid genes	220	54%	190	46%	410	225	52%	207	48%	432	842
Lymphoid genes	89	49%	94	51%	183	87	44%	111	56%	198	381
Control (CH-free)	43912	45%	53536	55%	97448	43621	45%	53844	55%	97465	194913

^a79 participants had both myeloid mutations and myeloid mCA

^bLymphoid CH was defined by lymphoid mCA and/or lymphoid mutations, without myeloid mutations or myeloid mCA. 30 participants had both lymphoid mutations and lymphoid mCA

^c14 participants had both myeloid and lymphoid mutations and were classed as myeloid

^d218 participants had more than one myeloid gene mutation